New study finds a large increase in food allergies in young children since 2008.
Articles on EpiPen
Displaying all articles
Recently passed legislation will ensure pharmaceutical companies report shortages of medicines. This is only about notifications. It won’t prevent medicine shortages themselves.
The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Why drug maker Mylan’s decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.
Top contributors
-
Associate professor, Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney
-
Associate Professor of Law, Washington University in St. Louis
-
Lecturer, Pharmacy Practice, University of Sydney
-
Professor of Law, University of Denver
-
Professor in Pharmacy Practice, University of Sydney
-
Professor of Economics, Loughborough University
-
Professor in Immunology, University of Manchester